The Australian government introduced a new Aged Care Act in 2024 and launched the Support at Home program on 1 November 2025. These changes focus on increasing fees for aged care services, especially...
A large Australian study found that two-thirds of people with Parkinson’s experience chronic pain. The research involved over 10,600 participants from the Australian Parkinson’s Genetics Study support...
The PBAC is close to deciding whether weight-loss drugs like semaglutide will be added to Australia's PBS. Currently, many patients pay up to $5000 a year for private prescriptions of GLP-1 therapies....
Australia’s health system is mainly focused on treating illness rather than preventing it. Public hospitals, private providers, and primary care are all under pressure. The country spends 10.3% of GDP...
The drug Saxenda (liraglutide), used for obesity and diabetes, will no longer be available in Australia after December 2025. Novo Nordisk decided to stop manufacturing Saxenda, shifting focus to its n...
In 2025, GLP-1 receptor agonists remained a major focus in healthtech, showing benefits like reduced heart failure risk, weight loss, and better blood sugar control. However, concerns about side effec...
Researchers studied over 19,000 US primary care patients with uncontrolled hypertension in 2021. They found that simply improving medication adherence or increasing medication doses did not significan...
The Global Hidradenitis Suppurativa Atlas (GHiSA) study shows that hidradenitis suppurativa (HS) affects about 1 in 100 people worldwide, including Australia. This challenges the idea that HS is a rar...
NSW has announced a $31.4 million expansion of the Hospital in the Home program. Starting December 2025, the program will be available across Bega Valley, Eurobodalla, Goulburn, and Queanbeyan. It aim...
Blood cancer is a major health issue for women in Australia. It has a higher diagnosis rate than ovarian and cervical cancers combined. Blood cancer is the second most common cancer in women and the m...
Eli Lilly Australia is preparing to submit orforglipron, an oral GLP-1 agonist, to the TGA. The drug was tested in the ATTAIN-2 trial, which involved over 1600 adults with obesity and type 2 diabetes...
Researchers from Arizona State University analysed data from the Dog Aging Project, which surveyed over 47,000 dog owners in the US. They found that between 2019 and 2023, about 7.3% of dogs had been...
The TGA official Robyn Langham criticised how companies have exploited rules around medicinal cannabis prescribing, especially via telehealth. She said some clinics are providing recreational access r...
Researchers at the Max Planck Institute in Germany studied pregnant mice fed with artificial bacon flavour. The mice that experienced the smell of fatty food during pregnancy showed signs of increased...
The Australian Cardiovascular Alliance (ACvA) released a report highlighting the lack of a consistent national data system for cardiovascular disease (CVD). Despite CVD being a leading cause of death,...
The World Health Organization has officially endorsed GLP-1 therapies like liraglutide, semaglutide, and tirzepatide for long-term obesity treatment in adults, excluding pregnant women. They recommend...
The Australian Cardiovascular Alliance (ACvA) has highlighted a major gap in national health data for cardiovascular disease (CVD). CVD causes one in four deaths in Australia, with a death every 12 mi...
Researchers from the Hopkins Lupus Cohort studied 1768 patients with systemic lupus erythematosus over more than 11,000 person-years. They found that patients with low baseline vitamin D levels, below...
The 2025 American Heart Association conference showcased several key findings relevant to Australian healthtech. The OPTIMA-AF trial found that a one-month course of clot-preventing medication after s...
Australia’s first National Skin Cancer Scorecard has been launched by MSCAN and the Australasian College of Dermatologists. It highlights significant gaps in prevention, early detection, and care for...
